Group 1 - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2] - The lawsuit alleges that Edwards Lifesciences misrepresented the demand and growth potential of its Transcatheter Aortic Valve Replacement (TAVR) platform, claiming that patient activation activities were ineffective and that healthcare organizations prioritized other treatments [2][3] - Following a significant reduction in TAVR guidance and disappointing financial results announced on July 24, 2024, Edwards' stock price dropped by 31%, from $86.95 to $59.70 per share [3] Group 2 - Investors in Edwards Lifesciences are encouraged to seek legal options and submit their information to the law firm representing the case, with no upfront costs for shareholders [4] - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and has achieved notable recoveries in past cases, including over $900 million from Tesla, Inc. [4]

RADNOR, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Central District of California against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period") The lead plaintiff deadline is Dece ...

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024, both dates inclusive (the "Class Period"). A class action has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 13, 2024. So what: If you purchased Edwards Lifesciences Corporation se ...

Core Viewpoint - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws, with claims related to misleading statements about the company's TAVR platform and its market demand [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Patel v. Edwards Lifesciences Corporation, et al., No. 24-cv-02221 [2]. - Investors have until December 13, 2024, to request to lead the case [2]. Group 2: Company Overview - Edwards Lifesciences is an international company focused on heart valve repair and replacement therapies, as well as critical care monitoring solutions, categorized into four main therapy types: TAVR, TMTT, Surgical Structural Heart therapies, and Critical Care therapies [3]. Group 3: Allegations and Impact - The complaint alleges that Edwards misrepresented the demand for its TAVR platform, claiming significant unmet demand while the actual growth had stalled due to ineffective patient activation activities and prioritization of other treatments by healthcare organizations [4]. - On July 24, 2024, Edwards reduced its guidance for TAVR for fiscal 2024 and reported disappointing financial results for the second quarter, leading to a 31% decline in stock price from $86.95 to $59.70 per share [5][6].

NEW YORK, Oct. 17, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=108710&from=4 CLASS PERIOD: F ...

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 6, 2024 – July 24, 2024 Lead Plaintiff Deadline: Dec. 13, 2024 Visit: www.hbsslaw.com/investor-fraud/ew Contact the Firm Now: EW@hbsslaw.com 844-916-0895 Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences' disclosures about its ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons or entities who purchased or otherwise acquired Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"). The lawsuit seeks to recover damages for the Company's in ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=108481&from=3 CLASS PERIO ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Edwards Lifesciences (EW) reports results for the quarter ended September 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purchased or acquired the securities of Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) between February 6, 2024 and July 24, 2024, inclusive (the "Class Period"). For more information, submit a form at Edwards Lifesciences Corporation Shareholder Class Action Lawsuit, email Investor Relations Manager Pet ...